To evaluate whether the combination of DRP-104 with MEK/ERK inhibitors could reduce tumor growth or increase survival, DRP-104 was tested in the presence or absence of trametinib in PDAC syngeneic models (Fig. 6a). Here, MAP2K7 is linked to neoplasm.